|

Acalabrutinib Clinical Trials

29 actively recruiting trials across 18 locations

▼ -1 trial since August 2026

Also known as: ACP 196, ACP-196, ACP196, Bruton Tyrosine Kinase Inhibitor ACP-196, CALQUENCE® +2 more

Pipeline

Phase 1: 1Phase 2: 15Phase 3: 5Phase 4: 1Phase 1/2: 5

Top Sponsors

  • AstraZeneca5
  • Mayo Clinic2
  • City of Hope Medical Center2
  • Zulfa Omer1
  • The First Affiliated Hospital with Nanjing Medical University1

Indications

  • Cancer29
  • Chronic Lymphocytic Leukemia13
  • Small Lymphocytic Lymphoma8
  • Mantle Cell Lymphoma5
  • Diffuse Large B-Cell Lymphoma4

Other5 trials

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Phase 3
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
N/A
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Phase 2
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

Boston, Massachusetts4 trials

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site

Phase 1/2
Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital

Phase 1/2
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Research Site

Phase 2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Massachusetts General Hospital Cancer Center

Phase 2

Duarte, California3 trials

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

City of Hope National Medical Center

Phase 3
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 2
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Comprehensive Cancer Center

Phase 2

Columbus, Ohio2 trials

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 2

Mobile, Alabama1 trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

USA Mitchell Cancer Institute ( Site 0014)

Phase 3

Scottsdale, Arizona1 trial

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic in Arizona

Phase 2

Tucson, Arizona1 trial

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Arizona Oncology - Tucson - Rudasill /ID# 267552

Phase 3

Berkeley, California1 trial

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Research Site

Phase 2

Los Angeles, California1 trial

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2

Palo Alto, California1 trial

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stanford Cancer Institute Palo Alto

Phase 2

Atlanta, Georgia1 trial

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University Hospital/Winship Cancer Institute

Phase 2

Chicago, Illinois1 trial

Avo In R/R And Previously Untreated MCL

University of Chicago Medical Center

Phase 1/2

Goshen, Indiana1 trial

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Goshen Center for Cancer Care

Phase 1/2

Bethesda, Maryland1 trial

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 2

Charlotte, North Carolina1 trial

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Research Site

Phase 4

Cincinnati, Ohio1 trial

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

University of Cincinnati

Phase 2

Portland, Oregon1 trial

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute

Phase 1

Houston, Texas1 trial

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M D Anderson Cancer Center

Phase 2

Seattle, Washington1 trial

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.